drugset / Trial / NCT05852847
Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
Phase 2
Unknown
216 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Luhe Hospital · collabBeijing Tsinghua Changgeng Hospital · collabChina-Japan Friendship Hospital · collabChinese PLA General Hospital · collabNavy General Hospital, Beijing · collabPeking University First Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, randomized, controlled phase 2 trial to compare the efficacy and safety profiles in ITP patients receiving baricitinib plus danazol to those receiving danazol alone.
Timeline
- Start
- 2023-05-16
- Primary completion
- 2024-11
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Danazol | Other / unclassified | 200 mg | Oral |